Enzyme-linked Immunosorbent Assay for Detection of Immunoglobulin G Antibodies to Escherichia Coli Vero Cytotoxin 1

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 1994 Jun 1

PMID 8077389

Citations 23

Authors

M A Karmali

M Petric

M Winkler

M Bielaszewska

J Brunton

N van de Kar

T Morooka

G B Nair

S E Richardson

G S Arbus

Affiliations

Soon will be listed here.

Abstract

The frequency of Vero cytotoxin 1 (VT1)-neutralizing antibody (NAb) in serum specimens from 790 age-stratified (0 to 70 years) control individuals from Toronto was 61 of 790 (7.7%), with a peak of 19% in the 20- to 30-year-old age group and a second peak of 16.7% in the 60- to 70-year-old age group. A total of 568 serum specimens, including 538 from the 790 Toronto control subjects, 21 from patients from three outbreaks of VT-producing Escherichia coli (VTEC) infection, and 9 known VT1-NAb-positive serum specimens from patients with hemolytic-uremic syndrome (HUS), were then tested for the presence of anti-VT1 immunoglobulin G (IgG) by an enzyme-linked immunosorbent assay (ELISA). The mean ELISA values of 522 VT1-NAb-negative serum specimens and 46 VT1-NAb-positive serum specimens were 0.09 +/- 0.06 (range, 0 to 0.56) and 0.78 +/- 0.66 (range, 0.16 to 2.91), respectively (P < 0.001; Student's t test). With a breakpoint of 0.21 (mean ELISA value of the VT1-NAb-negative sera + 2 standard deviations), the sensitivity, specificity, positive predictive value, and negative predictive value of the VT1 IgG ELISA compared with those of the VT1-NAb assay were, respectively, 95.7, 98.7, 86.3, and 99.6%. There were nine discrepant serum specimens, of which seven were anti-VT1 IgG positive and VT1-NAb negative and two were anti-VT1 IgG negative and VT1-NAb positive. The ELISA was also used for testing 238 control serum specimens from The Netherlands, Japan, and India and acute- and convalescent-phase serum specimens from 42 Toronto patients with HUS. The frequencies of anti-VT1 IgG (with VT1-NAb frequencies in parantheses) in control sera from the Netherlands, Japan, and India were 6% (3%), 1.1% (0%), and 12% (10%), respectively, with no age clustering. The frequencies of anti-VT1 IgG seropositivity in HUS patients were 5 of 14 (35.7%) in patients with unknown toxin exposure, 2 of 22 (9.1%) in individuals with known exposure to VT1 plus VT2 or VT1 alone, and 0 of 6 (0%) in patients exposed to only VT2. Development of serum anti-VT1 IgG response appears to be the exception rather than the rule in sporadic HUS patients infected with VTEC expressing VT1. However, in two family outbreaks associated with VTEC strains expressing VT1 alone and VT1 plus VT2, respectively, the presence of anti-VT1 IgG in virtually all exposed individuals who remained symptom free suggests that the presence of antibody was associated with protection.

Citing Articles

SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences.

Abdelhamid A, Faraone J, Evans J, Liu S, Yousef A Pathogens. 2022; 11(8).

PMID: 36014958 PMC: 9415055. DOI: 10.3390/pathogens11080837.

Shiga Toxin-Producing Infections during Pregnancy.

Sacerdoti F, Scalise M, Burdet J, Amaral M, Franchi A, Ibarra C Microorganisms. 2018; 6(4).

PMID: 30360505 PMC: 6313425. DOI: 10.3390/microorganisms6040111.

The Polymorphic Aggregative Phenotype of Shiga Toxin-Producing Escherichia coli O111 Depends on RpoS and Curli.

Diodati M, Bates A, Miller W, Carter M, Zhou Y, Brandl M Appl Environ Microbiol. 2015; 82(5):1475-1485.

PMID: 26712542 PMC: 4771311. DOI: 10.1128/AEM.03935-15.

Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.

Guirro M, Piazza R, Souza R, Guth B BMC Infect Dis. 2014; 14:320.

PMID: 24919599 PMC: 4060089. DOI: 10.1186/1471-2334-14-320.

Oral administration of Shiga toxin-producing Escherichia coli induces intestinal and systemic specific immune response in mice.

Fernandez-Brando R, Cabrera G, Baschkier A, Mejias M, Panek C, Miliwebsky E Med Microbiol Immunol. 2014; 203(3):145-54.

PMID: 24399245 DOI: 10.1007/s00430-013-0325-y.

References

KONOWALCHUK J, Speirs J, Stavric S . Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977; 18(3):775-9. PMC: 421302. DOI: 10.1128/iai.18.3.775-779.1977. View

Lingwood C . Verotoxins and their glycolipid receptors. Adv Lipid Res. 1993; 25:189-211. View

Karmali M, Steele B, Petric M, Lim C . Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983; 1(8325):619-20. DOI: 10.1016/s0140-6736(83)91795-6. View

Riley L, Remis R, Helgerson S, McGEE H, Wells J, Davis B . Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983; 308(12):681-5. DOI: 10.1056/NEJM198303243081203. View

Karmali M, Petric M, Lim C, Fleming P, Arbus G, Lior H . The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985; 151(5):775-82. DOI: 10.1093/infdis/151.5.775. View

OBrien A, Holmes R . Shiga and Shiga-like toxins. Microbiol Rev. 1987; 51(2):206-20. PMC: 373104. DOI: 10.1128/mr.51.2.206-220.1987. View

de Grandis S, Ginsberg J, Toone M, Climie S, Friesen J, Brunton J . Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol. 1987; 169(9):4313-9. PMC: 213746. DOI: 10.1128/jb.169.9.4313-4319.1987. View

PAI C, Ahmed N, Lior H, Johnson W, Sims H, Woods D . Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. J Infect Dis. 1988; 157(5):1054-7. DOI: 10.1093/infdis/157.5.1054. View

Obrig T, Del Vecchio P, Brown J, Moran T, Rowland B, Judge T . Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988; 56(9):2373-8. PMC: 259575. DOI: 10.1128/iai.56.9.2373-2378.1988. View

10.

Richardson S, Karmali M, Becker L, Smith C . The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988; 19(9):1102-8. DOI: 10.1016/s0046-8177(88)80093-5. View

11.

Head S, Karmali M, Roscoe M, Petric M, Strockbine N, Wachsmuth I . Serological differences between verocytotoxin 2 and shiga-like toxin II. Lancet. 1988; 2(8613):751. DOI: 10.1016/s0140-6736(88)90228-0. View

12.

Karmali M . Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989; 2(1):15-38. PMC: 358098. DOI: 10.1128/CMR.2.1.15. View

13.

Lopez E, Diaz M, Grinstein S, Devoto S, MENDILAHARZU F, Murray B . Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis. 1989; 160(3):469-75. DOI: 10.1093/infdis/160.3.469. View

14.

Ostroff S, Tarr P, Neill M, Lewis J, Kobayashi J . Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989; 160(6):994-8. DOI: 10.1093/infdis/160.6.994. View

15.

Boulanger J, Petric M, Lingwood C, Law H, Roscoe M, Karmali M . Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1. J Clin Microbiol. 1990; 28(12):2830-3. PMC: 268288. DOI: 10.1128/jcm.28.12.2830-2833.1990. View

16.

Cohen A, Madrid-Marina V, Estrov Z, Freedman M, Lingwood C, Dosch H . Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990; 2(1):1-8. DOI: 10.1093/intimm/2.1.1. View

17.

Hii J, Gyles C, Morooka T, Karmali M, Clarke R, de Grandis S . Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J Clin Microbiol. 1991; 29(12):2704-9. PMC: 270418. DOI: 10.1128/jcm.29.12.2704-2709.1991. View

18.

Caprioli A, Luzzi I, Rosmini F, Pasquini P, Cirrincione R, Gianviti A . Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. J Infect Dis. 1992; 166(1):154-8. DOI: 10.1093/infdis/166.1.154. View

19.

Levine M, McEwen J, Losonsky G, Reymann M, Harari I, Brown J . Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol. 1992; 30(7):1636-41. PMC: 265356. DOI: 10.1128/jcm.30.7.1636-1641.1992. View

20.

OBrien A, Tesh V, Donohue-Rolfe A, Jackson M, Olsnes S, Sandvig K . Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992; 180:65-94. DOI: 10.1007/978-3-642-77238-2_4. View